A key bottleneck in the translation of discoveries from transcriptomic and proteomic screens into clinically viable diagnostics relates to current deficits in relation to antibody availability. This presentation provides a case example of how antibody-based proteomics can be applied to transition candidate breast cancer progression-related biomarkers from such omic screens.
Flow Chemistry